The global microneedle drug delivery systems market size is expected to reach USD 9.46 billion by 2030, registering a CAGR of 7.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. Growing demand for safer alternatives to conventional hypodermic injection and increasing awareness about minimally invasive and pain-free administration of drugs is expected to boost the market growth for microneedle drug delivery systems. Furthermore, increasing cases of diabetes are also expected to boost the market growth. For instance, as per the estimates of the World Health Organization (WHO) in 2021, approximately 463 million adults were living with diabetes, worldwide, representing 9.3% of the global population.
Microneedles offer several advantages over traditional drug delivery methods, such as oral or transdermal routes. Studies have shown that drug delivery by microneedles can improve drug absorption, bioavailability and efficacy, especially for drugs with poor water solubility or low permeability. For instance, a study published in "Journal of Controlled Release" showed that transdermal delivery of insulin using microneedles was more effective than subcutaneous injection.
The COVID-19 pandemic had a significant impact on drug delivery by microneedles. The major impact of the pandemic on the market was the increased demand for vaccine delivery. Microneedles have been explored as a potential delivery method for the COVID-19 vaccines due to their ease of use, low cost, and potential to induce a strong immune response. The pandemic has accelerated development of the microneedle-based vaccine delivery systems, with several companies and academic institutions working on COVID-19 vaccine patches.
However, the pandemic has also disrupted global supply chains, which has affected the production and distribution of microneedle-based drug delivery systems. Some manufacturers have faced challenges in obtaining raw materials and components, which has resulted in supply shortages and increased prices.
Request a free sample copy or view report summary: Microneedle Drug Delivery Systems Market Report
The hollow microneedle segment accounted for the largest revenue share in 2022, since they are considered ideal for the use of vaccine and hormonal therapy patients
Dissolving microneedle segment is expected to grow at the fastest rate during the forecast period, as it only requires one step, the microneedle needs not be removed after insertion
The metal material segment accounted for the highest revenue share in 2022; stainless steel and titanium are the most frequently employed metals
By application, drug delivery segment dominated the market in 2022
The vaccine segment is expected to experience the fastest growth rate during the forecast period due to the increased awareness of vaccination among populations
Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period due to the presence of untapped opportunities in the emerging economies of China and India
Grand View Research has segmented the global microneedle drug delivery systems market based on the type, material, application, and region:
Microneedle Drug Delivery Systems Type Outlook (Revenue, USD Million, 2018 - 2030)
Solid
Hollow
Dissolving
Coated
Others
Microneedle Drug Delivery Systems Material Outlook (Revenue, USD Million, 2018 - 2030)
Silicon
Metal
Polymer
Others
Microneedle Drug Delivery Systems Application Outlook (Revenue, USD Million, 2018 - 2030)
Dermatology
Drug Delivery
Pain Management
Cancer Therapy
Vaccine Delivery
Others
Microneedle Drug Delivery Systems Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Norway
Sweden
Denmark
Asia Pacific
China
Japan
India
Thailand
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
UAE
Kuwait
List of Key Players in the Microneedle Drug Delivery Systems Market
Raphas
Novartis International AG
Becton Dickinson and Company
B. Braun
NanoPass technologies limited
Termo
Smiths Medical
Cardinal Health
3M
"The quality of research they have done for us has been excellent..."